# Bionano Genomics, Inc. (BNGO) · Edgar & Edgarette company card

> Bionano Genomics (BNGO) saw revenue fall 7.4% in FY2025 to $29 million, operating margin -117% against a -1.0% median for laboratory analytical instruments, equity 60.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1411690 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BNGO) · [JSON](https://www.pops4.com/boards/company/BNGO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $29M |
| Revenue growth, 1 year | -7.4% |
| Revenue growth per year | 12.2% |
| Operating margin | -116.9% (prior year -337.9%) |
| Net margin | -92.6% |
| Operating cash flow | −$16M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $74M |
| Total equity | $44M |
| Equity ÷ assets | 60.4% |
| Return on equity | -59.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -31.33 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -3.45 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; revenue is hard to predict: its 80% range is ±59%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $28.5M (FY2025). Experience: revenue down 7.4% on the year, up 12.2% a year over 4 years; operating margin -116.9%, up from -337.9%. Soundness: equity 60.4% of assets, return on equity -59.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $13.7M and $53.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $12.5M to $59.0M. A statistical range, not company guidance. Against peers (12 filers, $50M+ revenue, laboratory analytical instruments): operating margin -116.9% against a -1.0% median; growth -7.4% against 1.1%.

Range logged 2026-10-28, receipt b0e062ec79ac8d73, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-05 ([filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000036/0001411690-26-000036-index.htm))

## Recent filings

- S-1 · filed 2026-10-27 · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000119312526434439/0001193125-26-434439-index.htm)
- 8-K · filed 2026-09-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000046/0001411690-26-000046-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000044/0001411690-26-000044-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/0001411690-26-000043-index.htm)
- 8-K · filed 2026-06-24 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000040/0001411690-26-000040-index.htm)
- 8-K · filed 2026-06-05 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000036/0001411690-26-000036-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001411690.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1411690

## Cite

POPS4, Edgar & Edgarette: Bionano Genomics, Inc. (BNGO) company card, from the company's own SEC filings, accessed 2026-10-28, https://www.pops4.com/boards/company/BNGO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.